All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10376761" target="_blank" >RIV/00216208:11110/18:10376761 - isvavai.cz</a>

  • Alternative codes found

    RIV/00669806:_____/18:10376761 RIV/00023728:_____/18:N0000049

  • Result on the web

    <a href="https://doi.org/10.1007/s40271-017-0285-1" target="_blank" >https://doi.org/10.1007/s40271-017-0285-1</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/s40271-017-0285-1" target="_blank" >10.1007/s40271-017-0285-1</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis

  • Original language description

    Background: Clinical trials and observational studies lacking measures of health-related quality of life (QoL) are often inapplicable when conducting cost-effectiveness analyses using quality-adjusted life-years (QALYs). The only solution is to map QoL ex post from additionally collected clinical outcomes and generic QoL instruments. Nonetheless, mapping studies are absent in psoriatic arthritis (PsA). Methods: In this 2-year, prospective, multicentre, non-interventional study of PsA patients, EQ-5D and key clinical parameters such as Disease Activity in PsA (DAPsA), clinical DAPsA (cDAPsA; DAPsA without C-reactive protein [CRP]), and Health Assessment Questionnaire disability index (HAQ) were collected. We employed a linear mixed-effect regression model (ME) of the longitudinal dataset to explore the best predictors of QoL. Results: A total of 228 patients were followed over 873 appointments/observations. DAPsA, cDAPsA and HAQ were stable and highly significant predictors of EQ-5D utilities in both cross-sectional and longitudinal analyses. The best prediction was provided using a linear ME with HAQ and cDAPsA or DAPsA. A HAQ increase of 1 point represented a decrease in EQ-5D by -0.204 or -0.203 (p &lt; 0.0001); a one-point increase in cDAPsA or DAPsA dropped EQ-5D equally by -0.005 (p &lt; 0.0001). The ME revealed steeper and more accurate association compared with cross-sectional regressions or non-linear models/transformations. Conclusions: This is the first mapping study conducted in PsA and we hope that our study will encourage further mapping studies in PsA. The results showed that in cases where CRP is absent, cDAPsA provides similar results to DAPsA in predicting QoL.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30226 - Rheumatology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2018

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Patient

  • ISSN

    1178-1653

  • e-ISSN

  • Volume of the periodical

    11

  • Issue of the periodical within the volume

    3

  • Country of publishing house

    NZ - NEW ZEALAND

  • Number of pages

    12

  • Pages from-to

    329-340

  • UT code for WoS article

    000432014700007

  • EID of the result in the Scopus database

    2-s2.0-85034648572